{"classes":[{"categories":[{"measurements":[{"comment":"Only 1 patient","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"3.4"},{"groupId":"OG002","lowerLimit":"3.4","upperLimit":"18.0","value":"9.2"},{"groupId":"OG003","lowerLimit":"2.9","upperLimit":"5.5","value":"4.2"},{"comment":"Only 1 patient","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"10.6"},{"comment":"Not reached","groupId":"OG006","lowerLimit":"2.9","upperLimit":"NA","value":"8.6"},{"groupId":"OG007","lowerLimit":"4.0","upperLimit":"5.4","value":"4.7"},{"groupId":"OG008","lowerLimit":"4.1","upperLimit":"6.2","value":"5.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"38"}],"units":"Participants"}],"description":"Duration of Response by Investigator's Assessment, defined as the time between the date when the response criteria (PR or CR, whichever one is first reached) are fulfilled to the first date when disease progression (PD), recurrence or death is documented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with Pathologically proven diagnosis of biliary tract carcinoma","id":"OG000","title":"Biliary Tract Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of carcinoma of unknown primary site","id":"OG001","title":"Carcinoma of Unknown Primary Site Cohort"},{"description":"Patients with pathologically proven diagnosis of endometrial carcinoma","id":"OG002","title":"Endometrial Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of Ewing's Family of Tumors","id":"OG003","title":"Ewing's Family of Tumors Cohort"},{"description":"Patients with pathologically proven diagnosis of Germ Cell Tumors, excluding immature teratoma, or teratoma with malignant transformation.","id":"OG004","title":"Germ Cell Tumors Cohort"},{"description":"Patients with Pathologically proven diagnosis of Head and Neck Carcinoma. Salivary glands tumors were excluded.","id":"OG005","title":"Head and Neck Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of BRCA1/2-associated metastatic breast carcinoma","id":"OG006","title":"BRCA1/2-associated Metastatic Breast Carcinoma Cohort"},{"description":"Patients with Pathologically proven diagnosis of Neuroendocrine Tumors, grade 2 and 3 according to World Health Organization (WHO) classification.","id":"OG007","title":"Neuroendocrine Tumors Cohort"},{"description":"Patients with pathologically proven diagnosis of small cell lung cancer","id":"OG008","title":"Small Cell Lung Cancer Cohort"}],"paramType":"MEDIAN","populationDescription":"Patients with response to treatment","reportingStatus":"POSTED","timeFrame":"From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}